Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

NCT05577715 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT05577715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05577715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Terminated
Start date
November 14, 2022
Completion date
August 12, 2024
Enrollment
31 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung